In one case series, different cardiac diseases with varying grades of toxicity were reported in patients under PD-1 inhibitor (pembrolizumab) with or without cardiotoxic pretreatment (radiotherapy, immunotherapy, and targeted cancer drugs) [57]. The gene discussed is PDCD1; the disease is cancer.